These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38548579)

  • 21. Pharmacotherapeutic management of pulmonary sarcoidosis.
    Fazzi P
    Am J Respir Med; 2003; 2(4):311-20. PubMed ID: 14719997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current therapy in sarcoidosis, the role of existing drugs and future medicine.
    Vorselaars AD; van Moorsel CH; Deneer VH; Grutters JC
    Inflamm Allergy Drug Targets; 2013 Dec; 12(6):369-77. PubMed ID: 24151828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pulmonary sarcoidosis: A comprehensive review: Past to present.
    Belperio JA; Fishbein MC; Abtin F; Channick J; Balasubramanian SA; Lynch Iii JP
    J Autoimmun; 2023 Oct; ():103107. PubMed ID: 37865579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosis and Treatment of Pulmonary Sarcoidosis: A Review.
    Belperio JA; Shaikh F; Abtin FG; Fishbein MC; Weigt SS; Saggar R; Lynch JP
    JAMA; 2022 Mar; 327(9):856-867. PubMed ID: 35230389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxic agents in sarcoidosis: which one should we choose?
    Vorselaars AD; Cremers JP; Grutters JC; Drent M
    Curr Opin Pulm Med; 2014 Sep; 20(5):479-87. PubMed ID: 25046427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthetic pharmacotherapy for pulmonary sarcoidosis.
    Llabres M; Brito-Zerón P; Ramos-Casals M; Sellares J
    Expert Opin Pharmacother; 2019 Aug; 20(11):1397-1404. PubMed ID: 31090462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Right care, first time: a highly personalised and measurement-based care model to manage youth mental health.
    Hickie IB; Scott EM; Cross SP; Iorfino F; Davenport TA; Guastella AJ; Naismith SL; Carpenter JS; Rohleder C; Crouse JJ; Hermens DF; Koethe D; Markus Leweke F; Tickell AM; Sawrikar V; Scott J
    Med J Aust; 2019 Nov; 211 Suppl 9():S3-S46. PubMed ID: 31679171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sarcoidosis - a multisystem disease.
    Franzen DP; Brutsche M; Nilsson J; Böni C; Daccord C; Distler O; Elsener D; Funke-Chambour M; Gruner C; Hayward-Könnecke H; Hostettler KE; Kündig T; Ribi C; Seebach JD; Seeger H; Vrugt B; Kolios AGA
    Swiss Med Wkly; 2022 Jan; 152():w30049. PubMed ID: 35072393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Sarcoidosis as prime example of a granulomatous disease].
    Oqueka T; Galow S; Simon M; Weidmann A; Stübiger N; Zengin-Sahm E; Sinning C; Krusche M; Ruffer N; Steurer S; Schick-Bengardt X; Sebode M; Horst LJ; Steinmetz OM; Melderis S; Rosenkranz SC; Möller K; Jantke H; Klose H
    Z Rheumatol; 2022 Sep; 81(7):535-548. PubMed ID: 35927387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists.
    Melani AS; Bigliazzi C; Cimmino FA; Bergantini L; Bargagli E
    Pulm Ther; 2021 Dec; 7(2):325-344. PubMed ID: 34143362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Refractory Sarcoidosis: A Review.
    El Jammal T; Jamilloux Y; Gerfaud-Valentin M; Valeyre D; Sève P
    Ther Clin Risk Manag; 2020; 16():323-345. PubMed ID: 32368072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging Therapeutic Options for Refractory Pulmonary Sarcoidosis: The Evidence and Proposed Mechanisms of Action.
    Nelson NC; Kogan R; Condos R; Hena KM
    J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sarcoidosis: Evaluation and Treatment.
    Partin M; Clebak KT; Chen R; Helm M
    Am Fam Physician; 2024 Jan; 109(1):19-29. PubMed ID: 38227868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of extrapulmonary sarcoidosis: challenges and solutions.
    Al-Kofahi K; Korsten P; Ascoli C; Virupannavar S; Mirsaeidi M; Chang I; Qaqish N; Saketkoo LA; Baughman RP; Sweiss NJ
    Ther Clin Risk Manag; 2016; 12():1623-1634. PubMed ID: 27853374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sepsis Care Pathway 2019.
    Labib A
    Qatar Med J; 2019; 2019(2):4. PubMed ID: 31763206
    [No Abstract]   [Full Text] [Related]  

  • 38. New molecular targets for the treatment of sarcoidosis.
    Chiarchiaro J; Chen BB; Gibson KF
    Curr Opin Pulm Med; 2016 Sep; 22(5):515-21. PubMed ID: 27454074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies for identifying pulmonary sarcoidosis patients at risk for severe or chronic disease.
    Judson MA
    Expert Rev Respir Med; 2017 Feb; 11(2):111-118. PubMed ID: 28076979
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.